NHS England | April 2020 | NHS strikes deal on first in a new generation of cancer busting drugs
The NHS has struck a deal which will see hundreds of people a year benefit from a ‘game-changing’ new cancer treatment.
Larotrectinib, will initially be used for children, young people and some adults, and targets tumours according to their genetic make-up, rather than where they originated from in the body.
The revolutionary treatment is the first in a new generation of ‘tumour agnostic’ drugs to be made available on the NHS following the deal endorsed by NICE, the organisation that ensures clinical and cost effectiveness.
Larotrectinib, also known as Vitrakvi, can be used against a wide range of cancers and could offer hope to patients with rare forms of the disease that may previously have been untreatable.
Further details available from NHS England